[⁶⁸Ga]Ga-P16-093 as a PSMA-Targeted PET Radiopharmaceutical for Detection of Cancer: Initial Evaluation and Comparison with [⁶⁸Ga]Ga-PSMA-11 in Prostate Cancer Patients Presenting with Biochemical Recurrence.

ABSTRACT:

Purpose

This study was undertaken to evaluate radiation dosimetry for the prostate-specific membrane antigen targeted [⁶⁸Ga]Ga-P16-093 radiopharmaceutical, and to initially assess agent performance in positron emission tomography (PET) detection of the site of disease in prostate cancer patients presenting with biochemical recurrence.

Procedures

Under IND 133,222 and an IRB-approved research protocol, we evaluated the biodistribution and pharmacokinetics of [⁶⁸Ga]Ga-P16-093 with serial PET imaging following intravenous administration to ten prostate cancer patients with biochemical recurrence. The recruited subjects were all patients in whom a recent [⁶⁸Ga]Ga-PSMA-11 PET/X-ray computed tomography (CT) exam had been independently performed und

SUBMITTER: Green MA 

PROVIDER: S-EPMC7028523 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature